By Alexander Bueso
Date: Tuesday 26 Jan 2021
LONDON (ShareCast) - (Sharecast News) - Regeneron Pharmaceuticals antibody cocktail severely curtails Covid-19 symptoms and infections, the results of a late-stage trial showed.
The trial involving 400 patients with at least one household member sick from Covid-19 showed that the two-antibody cocktail, known as REGEN-COV, completely cut symptomatic infections of the novel coronavirus.
Overall rates of infections meanwhile were reduced by approximately half.
A rival treatment from Eli Lilly, bamlanivimab, had shown a similar efficacy the week before, reducing Covid-19 infections among nursing home resident in a trial by 80%.
As of 1650 GMT, Regeneron shares had slipped 1.11% to $542.14.
Email this article to a friend
or share it with one of these popular networks:
| Currency | US Dollars |
| Share Price | $ 763.23 |
| Change Today | $ -13.08 |
| % Change | -1.68 % |
| 52 Week High | $787.32 |
| 52 Week Low | $490.81 |
| Volume | 835,909 |
| Shares Issued | 107.80m |
| Market Cap | $82,276m |
| RiskGrade | 129 |
| Strong Buy | 9 |
| Buy | 10 |
| Neutral | 7 |
| Sell | 2 |
| Strong Sell | 0 |
| Total | 28 |

| Time | Volume / Share Price |
| 15:59 | 112 @ $763.21 |
| 15:59 | 80 @ $763.00 |
| 15:59 | 40 @ $762.81 |
| 15:59 | 40 @ $762.84 |
| 15:59 | 40 @ $763.05 |
You are here: research